ArticleCancers2022

Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.

Takuto Shimizu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.